Investigational drug · Phase 2
Rimonabant
Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Chronic Stroke, Subacute Stroke, Post-COVID-19 Syndrome.
Phase 2Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
4
4 still active
All registered trials
52
Any phase or sponsor naming "Rimonabant"
First trial start
2026
May 13, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Rimonabant", any sponsor or status.
Conditions studied
As listed on its trial records.
- Chronic Stroke
- Subacute Stroke
- Post-COVID-19 Syndrome
- Cervical Spinal Cord Injury
Approved drugs for the same conditions: Stroke prevention · COVID-19 · Cardiovascular and metabolic · Infectious disease and vaccines · Rare and genetic disease
Largest trials
Live from ClinicalTrials.gov: studies naming "Rimonabant" as an intervention, largest first.
- Comprehensive Rimonabant Evaluation Study of Cardiovascular ENDpoints and OutcomesPivotal-lookingTerminated
SanofiSanofi (SNY)
NCT00263042 · 18,695 participants · Start Dec 2005 · Primary completion Apr 2009
Drug: Rimonabant; Placebo (for Rimonabant) · For: Cardiovascular Disease
Sites: Bridgewater, New Jersey; Buenos Aires, Argentina; Macquarie Park, Australia · 43 sites in all
- Efficacy and Safety of Rimonabant as an Aid to Maintenance of Smoking CessationPivotal-lookingCompleted
SanofiSanofi (SNY)
NCT00459173 · 4,850 participants · Start Nov 2002 · Primary completion Sep 2005
Drug: rimonabant (SR141716) · For: Maintenance of Smoking Cessation
Sites: Bridgewater, New Jersey; Cove, Australia; Laval, Canada
- Obese Patients With or Without Comorbidities (RIO-North America)Pivotal-lookingCompleted
SanofiSanofi (SNY)
NCT00029861 · 3,045 participants · Start Aug 2001 · Primary completion Apr 2004
Drug: Rimonabant (SR141716) · For: Obesity; Weight Loss
Sites: Birmingham, Alabama; Phoenix, Arizona; Concord, California · 51 sites in all
- Early Detection of Atherosclerosis: a Randomized Trial in the Primary Prevention of Cardiovascular Diseases.Pivotal-lookingStatus unknown
Hospital Arnau de VilanovaAcademic, hospital or other
NCT00734123 · 2,948 participants (planned) · Start Apr 2008 · Primary completion Apr 2009
Drug: Simvastatin or Atorvastatin; Enalapril and 2 more · For: Atherosclerosis; Cardiovascular Diseases
Sites: Lleida, Spain
- Rimonabant in Abdominally Obese Patients With Impaired Fasting Blood GlucosePivotal-lookingTerminated
SanofiSanofi (SNY)
NCT00405808 · 2,666 participants · Start Dec 2006 · Primary completion Feb 2009
Drug: Rimonabant; Placebo · For: Obesity
Sites: Vienna, Austria; Diegem, Belgium; São Paulo, Brazil · 27 sites in all
- Rimonabant In Prediabetic Subjects To Delay Onset Of Type 2 DiabetesPivotal-lookingTerminated
SanofiSanofi (SNY)
NCT00325650 · 2,420 participants · Start May 2006 · Primary completion Mar 2009
Drug: Rimonabant; Placebo (for Rimonabant) · For: Prediabetic State
Sites: Bridgewater, New Jersey
- Rimonabant in Obesity Over a 2-Year Duration (RIO-Europe)Pivotal-lookingCompleted
SanofiSanofi (SNY)
NCT00386061 · 1,507 participants · Start Oct 2001 · Primary completion Jun 2004
Drug: rimonabant (SR141716) · For: Obesity
Sites: Bridgewater, New Jersey; Brussels, Belgium; Helsinki, Finland · 7 sites in all
- Obese Patients With Type 2 DiabetesPivotal-lookingCompleted
SanofiSanofi (SNY)
NCT00029848 · 1,045 participants · Start Oct 2001 · Primary completion May 2004
Drug: Rimonabant (SR141716) · For: Obesity; Diabetes Mellitus, Non-Insulin-Dependent; Obesity in Diabetes
Sites: Birmingham, Alabama; Phoenix, Arizona; Tucson, Arizona · 55 sites in all
- Obese Patients With Untreated DyslipidemiasPivotal-lookingCompleted
SanofiSanofi (SNY)
NCT00029835 · 1,033 participants · Start Sep 2001 · Primary completion Nov 2003
Drug: Rimonabant (SR141716) · For: Obesity; Dyslipidemia
Sites: Mesa, Arizona; Tucson, Arizona; Irvine, California · 35 sites in all
- Japanese Study of Rimonabant in Obese Patients With Dyslipidemia (VENUS)Pivotal-lookingTerminated
SanofiSanofi (SNY)
NCT00434096 · 915 participants · Start Feb 2007 · Primary completion Nov 2008
Drug: rimonabant (SR141716); placebo · For: Obesity
Sites: Tokyo, Japan
Newest research
PubMed records naming it or its code names, newest first.
- Acetaminophen alters endogenous lipid signaling and attenuates pathological pain through a mechanism requiring diacylglycerol lipase, monoacylglycerol lipase and cannabinoid CB1 receptors in mice.
Jesus CHA, Wirt JL, Woodward T, et al. · Neuropharmacology 2026
- Enhancement of 2-arachidonoylglycerol but not anandamide signaling in the ventral tegmental area selectively increases the choice to respond to reward-predictive incentive cues in male rats.
Leigh MPK, Colangelo J, Feja M, et al. · Neuropharmacology 2026
- The pharmacotherapy for pediatric obesity: insights and challenges from adult weight-loss medications.
Chen Z, Zhou Y, Li G, et al. · J Diabetes Metab Disord 2026
- CB1 receptor inhibition restores synaptoneurosomal alternative splicing landscape in fragile X syndrome mice.
Reyes-Ramírez LL, Ciaran-Alfano L, Reixachs-Solé M, et al. · iScience 2026
- Tolerance, physical dependence, and Ɗ9-THC-like interoceptive effects of cannabinol in mice.
Vanegas SO, Marusich JA, Maturano J, et al. · Drug Alcohol Depend 2026
- Discovery of a Peripherally Directed CB1 Receptor Antagonist That Restores Insulin Signaling in Adipocytes.
Azuaje J, Prieto-Díaz R, Gioé-Gallo C, et al. · ACS Omega 2026
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.